Details

Autor(en) / Beteiligte

• Noriega, Víctor
• Martínez-Laperche, Carolina
• Buces, Elena
• Pion, Marjorie
• Sánchez-Hernández, Noemí
• Martín-Antonio, Beatriz
• Guillem, Vicent
• Bosch-Vizcaya, Anna
• Bento, Leyre
• González-Rivera, Milagros
• Balsalobre, Pascual
• Kwon, Mi
• Serrano, David
• Gayoso, Jorge
• de la Cámara, Rafael
• Brunet, Salut
• Rojas-Contreras, Rafael
• Nieto, José B
• Martínez, Carmen
• Gónzalez, Marcos
• Espigado, Ildefonso
• Vallejo, Juan C
• Sampol, Antonia
• Jiménez-Velasco, Antonio
• Urbano-Ispizua, Alvaro
• Solano, Carlos
• Gallardo, David
• Díez-Martín, José L
• Buño, Ismael

Titel

The Genotype of the Donor for the .sub.n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation

Ist Teil von

• PloS one, 2015-10, Vol.10 (10), p.e0140454

Ort / Verlag

Public Library of Science

Erscheinungsjahr

2015

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• The FOXP3 gene encodes for a protein (Foxp3) involved in the development and functional activity of regulatory T cells (CD4+/CD25+/Foxp3+), which exert regulatory and suppressive roles over the immune system. After allogeneic stem cell transplantation, regulatory T cells are known to mitigate graft versus host disease while probably maintaining a graft versus leukemia effect. Short alleles ([less than or equal to](GT).sub.15) for the (GT).sub.n polymorphism in the promoter/enhancer of FOXP3 are associated with a higher expression of FOXP3, and hypothetically with an increase of regulatory T cell activity. This polymorphism has been related to the development of auto- or alloimmune conditions including type 1 diabetes or graft rejection in renal transplant recipients. However, its impact in the allo-transplant setting has not been analyzed. In the present study, which includes 252 myeloablative HLA-identical allo-transplants, multivariate analysis revealed a lower incidence of grade III-IV acute graft versus host disease (GVHD) in patients transplanted from donors harboring short alleles (OR = 0.26, CI 0.08-0.82, p = 0.021); without affecting chronic GVHD or graft versus leukemia effect, since cumulative incidence of relapse, event free survival and overall survival rates are similar in both groups of patients.